Cosmos Health Inc.

Cosmos Health has repurchased an additional 274,000 shares of its common stock in the open market at an average price of approximately $0.2554 per share, bringing the total shares repurchased under its previously announced $5 million share repurchase program to 5,112,000 shares for approximately $1.11 million. The company intends to continue making open market repurchases, subject to market conditions, under the program which expires on December 31, 2026 and may be renewed at the company's sole discretion. CEO Greg Siokas stated that reaching over five million shares repurchased underscores the company's commitment to the program and its belief that the shares remain undervalued.

Cosmos Health has entered a five-year agreement with Libytec Pharmaceutical to commercialize its type-2 diabetes medication DIABIT-IS X in Greece. Under the deal, Cosmos Health will supply the sitagliptin-based generic, while Libytec handles distribution and promotion to physicians, pharmacies, and hospitals. DIABIT-IS X is a generic alternative to Merck's Januvia, which together with Janumet generated approximately $4.5 billion in combined global sales in 2022. As a prescription medicine, it is expected to be accessible through Greece's national health insurance system, broadening its potential reach. The partnership is expected to contribute to Cosmos Health's revenue and cash-flow visibility.

Cosmos Health has launched a subscription-based purchasing model for its proprietary consumer health brands. The model is currently live with NOOR Collagen, a proprietary product formulated with premium marine collagen tripeptide, and has achieved a repeat purchase rate above 60% and margins in excess of 50%. The company expects the model to provide recurring revenue, cash flow visibility, and stronger customer relationships, and plans to extend it to additional products globally. Cosmos Health manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union, and owns brands including Sky Premium Life, Mediterranation, bio-bebe, C-Sept, and C-Scrub.

Cosmos Health has repurchased an additional 80,000 shares at an average price of approximately $0.2503 per share, bringing total repurchases under its $5 million buyback program to 4,140,000 shares for about $831,000. The company intends to continue open market repurchases subject to market conditions, with the program expiring on December 31, 2026 and renewable at its discretion. CEO Greg Siokas stated the buybacks reflect a belief that shares trade well below intrinsic value and a commitment to long-term shareholder value.

Cosmos Health expects to report preliminary second-quarter 2026 revenue of approximately $19.4 million, up about 31.5% from $14.75 million a year earlier. For the first half of 2026, revenue is projected at roughly $37.3 million, a 31% increase from $28.46 million in the prior-year period. Separately, the company has repurchased an additional 0.23 million shares at an average price of about $0.2539 per share, bringing total buybacks to 3.87 million shares for approximately $0.758 million under its $5 million share repurchase program, which runs through December 31, 2026.

Cosmos Health has advanced its international patent application for a proprietary hydrogel weight management platform into the U.S., Europe, Australia, and Canada. The application, titled "Hydrogel for Body Weight Management," is now in the European regional phase and national phases in the other three jurisdictions, following the acquisition of the intellectual property from Cloudpharm by Cosmos Health's subsidiary Cana Laboratories. The technology, known as CCX0722, is a capsule that swells in the stomach to promote satiety without systemic absorption. Cosmos Health owns the technology outright with no licensing fees or third-party dependencies, and management views it as one of the company's most strategically significant proprietary assets. The global weight management market was estimated at $190.6 billion in 2025 and is projected to reach $562.2 billion by 2033.

Cosmos Health announced that its proprietary antiseptic solution C-Sept PRO has gained strong traction across leading public and private hospital groups in Greece, with annualized sales poised to exceed $1.3 million at a gross margin of approximately 72%. Average monthly sales surpassed $93,000 over the past six months and accelerated to more than $108,000 per month over the past three months, generating roughly $0.9 million in annualized gross profit. The product is a professional-grade antiseptic combining chlorhexidine gluconate and isopropyl alcohol, used routinely for surgical and daily hand disinfection, pre-operative skin preparation, and catheterization. The company views its hospital business as a new high-margin revenue stream with recurring demand and intends to expand into additional European markets using its GMP-certified manufacturing platform and distribution network.